|
Affiliation |
Faculty of Medicine College Hospital Department of Gastroenterology |
|
Title |
Assistant Professor |
|
Related SDGs |
|
UCHIYAMA Nomi
|
|
|
Papers 【 display / non-display 】
-
A novel 6 Fr inside biliary stent system for perihilar biliary drainage Reviewed
河上 洋, 内山 尚美, 畑田 紘志
Endoscopy 58 ( S 01 ) 160 - 162 2026.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Thieme Verlag KG
-
大園 芳範, 河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 内田 圭祐, 田村 穗高, 小牧 優里, 中村 憲一, 岩切 久芳, 蓮池 悟, 永田 賢治
BMC gastroenterology 2026.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a sodium-glucose cotransporter type-2 inhibitor, is widely used in patients with type 2 diabetes. Several clinical trials with Tofo have shown its beneficial effects in NAFLD patients with diabetes; however, currently, there are limited data on NAFLD patients without diabetes./C57Bl/6J mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) as a model of non-diabetic non-alcoholic steatohepatitis (NASH). The mice were fed either a normal diet or CDAHFD for 12 weeks, and received either vehicle or Tofo based on their assigned group for 12 weeks./Tofo treatment attenuated CDAHFD-induced liver steatosis and fibrosis. The percentage of monocyte-derived macrophages in the liver, which was significantly increased in the CDAHFD-fed mice, was reduced by Tofo treatment. Furthermore, Tofo treatment increased the hepatic protein and mRNA expression levels related to fatty acid oxidation, which was decreased in CDAHFD-fed mice. Additionally, Tofo treatment decreased the hepatic protein and mRNA expression levels related to fatty acid synthesis, which was increased in CDAHFD-fed mice./Tofo may be a potential candidate for inhibiting liver steatosis and fibrosis via an alternative pathway, unlike glucose metabolism, in NAFLD patients without diabetes.
-
Diagnosis of pancreaticobiliary maljunction Reviewed
Kawakami Hiroshi, Hatada Hiroshi, Uchiyama Naomi, Ogawa Souichiro
Tando 39 ( 4 ) 715 - 722 2025.10
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japan Biliary Association
Pancreaticobiliary maljunction (PBM) is a congenital malformation in which the pancreatic and bile ducts join anatomically outside the duodenal wall, forming a long abnormal common channel. In PBM, the common channel is longer than normal, which debilitates the effect of the sphincter on the pancreaticobiliary junction, allowing the reciprocal reflux of pancreatic juice and bile. Based on this anatomical abnormality, the reflux of pancreatic juice into the biliary tract (pancreatobiliary reflux) provokes higher rates of biliary cancers, and reflux of bile into the pancreatic duct (biliopancreatic reflux) may sometimes cause pancreatitis. In PBM patients, the gallbladder wall is often thickened, accompanied by epithelial hyperplasia. Ultrasonography (US) is often used as a screening modality. Therefore, US can be used to detect gallbladder wall thickening and intra- and extra-hepatic bile duct dilatation, and can depict the status of the PBM. US plays a key role in the pre-diagnosis of PBM.
-
特集 胆膵内視鏡処置具ガイド2025 [私のミニマルセットはこれ!] 結石除去② Reviewed
河上 洋, 内山 尚美, 畑田 紘志
消化器内視鏡 37 ( 10 ) 1310 - 1311 2025.10
Publishing type：Research paper (scientific journal) Publisher：東京医学社
-
特集 経口胆道鏡･膵管鏡を使い熟す! [経口胆道鏡] 経口胆道鏡による胆管癌の水平方向進展範囲診断 Reviewed
河上 洋, 畑田 紘志, 内山 尚美, 小川 宗一郎, 金子 博樹, 内田 圭祐, 田村 穂高, 大園 芳範
消化器内視鏡 37 ( 7 ) 918 - 923 2025.7
Publishing type：Research paper (scientific journal) Publisher：東京医学社